0000950170-25-103333
SEC filingBruker's Q2 2025 revenue declined slightly, with significant margin compression due to tariffs, FX, and acquisition costs.
For the three months ended June 30, 2025, Bruker reported total revenue of $797.4 million, a slight decrease of 0.4% compared to $800.7 million in the same period last year. The decline was primarily driven by a 10.2% drop in the BSI BioSpin segment, reflecting weaker demand in biopharma and industrial markets for life science instruments. This was partially offset by a 7.6% increase in the BSI CALID segment, which benefited from prior-year acquisitions.
Gross profit fell 6.9% to $357.9 million, with gross margin contracting 310 basis points to 44.9%. The margin compression was attributed to higher U.S. tariffs, foreign exchange headwinds from a declining U.S. dollar, and an unfavorable sales mix. Operating income plummeted 75.3% to $11.9 million, resulting in an operating margin of just 1.5%, down from 6.0% in the prior year. The decline was driven by lower gross profit, increased selling, general and administrative expenses (up 4.6% to $231.4 million), and higher research and development costs (up 8.7% to $100.2 million), largely due to the impact of prior-year acquisitions.
Net income attributable to Bruker Corporation was flat at $7.6 million, as a significant decrease in income tax provision (a benefit of $3.1 million vs. an expense of $16.1 million) offset the operating income decline. The effective tax rate for the quarter was not meaningful due to one-time favorable discrete events.
Management highlighted a challenging demand environment, particularly in pharma and industrial markets. In response, the company initiated a corporate-wide restructuring program in the second quarter of 2025, with additional charges expected in the third and fourth quarters. The program is expected to reduce annual costs by approximately $100 million to $120 million in 2026, affecting supply chain, manufacturing, commercial, administrative, and R&D functions. The company also noted the impact of new global trade tariffs and foreign exchange headwinds, which are expected to continue. No specific revenue or earnings guidance was provided for the remainder of 2025.
Bruker's operating cash flow turned sharply negative to ($62.5M) in H1 2025, despite reporting net income of $21.0M. The primary driver was a massive $105.3M increase in income taxes payable (net), reversing the prior period's $22.4M outflow, coupled with $45.7M in other working capital uses. Depreciation and amortization of $106.5M provided a partial offset, but deferred tax benefits ($38.6M) and other non-cash credits reduced cash generation.
Capital expenditures of $47.3M were virtually flat versus $46.0M in H1 2024, representing a modest 2.8% increase. This intensity remains in line with the company's investment in scientific instrument manufacturing. Notably, cash paid for acquisitions surged to $69.5M (H1 2024: $1,576.5M), indicating a strategic pivot to smaller bolt-on deals versus the prior year's large acquisition.
Free cash flow (CFO minus capex) was deeply negative at ($109.8M) for H1 2025 (H1 2024: ($23.1M)). Despite this, the company continued paying $15.3M in dividends and repurchased $10.0M in stock. These capital returns were covered entirely by net financing cash flow of $44.3M, which included $308.2M in new revolving credit borrowings. The negative FCF and reliance on debt underscore significant working capital and tax-related pressures during the period.